This Insider Sold 2354.0 Shares In Health Catalyst Inc. (HCAT)


Health Catalyst Inc. (NASDAQ:HCAT) remained unchanged to $13.15 after subtracting $0.0 on Wednesday. The 5-day average trading volume is 704,205 shares of the company’s common stock. It has gained $13.55 in the past week and touched a new high 4 times within the past 5 days. An average of 590,401 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 642,587.

HCAT’s 1-month performance is 22.90% or $2.69 on its low of $9.76 reached on 12/28/22. The company’s shares have touched a 52-week low of $6.40 and high of $31.08, with the stock’s rally to the 52-week high happening on 01/24/23. YTD, HCAT has achieved 23.71% or $2.36 and has reached a new high 11 times. However, the current price is down -57.69% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Insider Transactions

HCAT stock investors last saw insider trading activity on Jan 18.Hunt Bryan Truman (Chief Financial Officer) most recently sold 2,354 shares at $12.53 per share on Jan 18. This transaction cost the insider $29,503. Chief Financial Officer, Hunt Bryan Truman, sold 2,055 shares at a price of $12.00 on Jan 17. Then, on Jan 17, Chief People Officer Llewelyn Linda sold 642 shares at a price of $12.12 per share. This transaction amounted to $7,781.

Valuation Metrics

HCAT stock has a beta of 1.20. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.62 while the price-to-book (PB) in the most recent quarter is 1.62.

Health Catalyst Inc.’s quick ratio for the period ended September 29 was 4.90, with the current ratio over the same period at 4.90. In terms of profitability, the gross margin trailing 12 months is 49.20%. The firm’s gross profit as reported stood at $117.57 million against revenue of $241.93 million.

Earnings Surprise

For the quarterly period ending September 29 this year, Health Catalyst Inc.’s cash and short-term investments amounted to $255.92 million against total debt of $248.2 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 12.53% to -$45.74 million, while revenue of -$33.43 million was 26.91% off the previous quarter. Analysts expected HCAT to announce -$0.19 per share in earnings in its latest quarter, but it posted -$0.13, representing a 31.60% surprise. EBITDA for the quarter stood at more than -$32.97 million. HCAT stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 336.23 million, with total debt at $248.2 million. Shareholders hold equity totaling $54.75 million.

Let’s look briefly at Health Catalyst Inc. (HCAT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 68.32% to suggest the stock is trending Neutral, with historical volatility in this time period at 35.46%.

The stock’s 5-day moving average is $13.03, reflecting a +4.42% or $0.55 change from its current price. HCAT is currently trading +26.12% above its 20-day SMA, +8.25% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +42.12% and SMA200 by-47.43%.

Stochastic %K and %D was 90.39% and 91.62% and the average true range (ATR) pointed at 0.73. The RSI (14) points at 65.94%, while the 14-day stochastic is at 84.66% with the period’s ATR at 0.71. The stock’s 9-day MACD Oscillator is pointing at 0.49 and 1.20 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Health Catalyst Inc. (NASDAQ: HCAT), Evercore ISI downgraded it to an In-line rating. They previously had an Outperform rating on the stock.


Please enter your comment!
Please enter your name here